New Data For Galvus® Provide Further Evidence Of Robust Efficacy And Tolerability In Treating Patients With Type 2 Diabetes

Uncontrolled patients with type 2 diabetes treated with metformin, one of the most prescribed oral medicines for this disease, were four times more likely to achieve recommended blood sugar control levels by adding Galvus (vildagliptin) to their treatment compared to those who added a placebo, according to new clinical data1. The study of 544 patients with type 2 diabetes who were inadequately controlled on metformin showed that 35.5% achieved glycemic control (HbA1c [click link for full article]

More: continued here

Filed under: Diabetes on September 20th, 2007